Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies - Wikidata - awgldk - TriplyDB

Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies

Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies

http://www.wikidata.org/entity/Q27684112

about

Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain.Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2.Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423 Analysis of the evolution and structure of a complex intrahost viral population in chronic hepatitis C virus mapped by ultradeep pyrosequencing.High-throughput sequencing analysis of post-liver transplantation HCV E2 glycoprotein evolution in the presence and absence of neutralizing monoclonal antibody.Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody.Longitudinal Sequence and Functional Evolution within Glycoprotein E2 in Hepatitis C Virus Genotype 3a Infection Immunoglobulin with High-Titer In Vitro Cross-Neutralizing Hepatitis C Virus Antibodies Passively Protects Chimpanzees from Homologous, but Not Heterologous, Challenge Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance.Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge.Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A.Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1 Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics Hepatitis C Virus Resistance to Carbohydrate-Binding Agents Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen.Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design.Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies.The past, present and future of neutralizing antibodies for hepatitis C virus.HCV E2 core structures and mAbs: something is still missing.Role of Conserved E2 Residue W420 in Receptor Binding and Hepatitis C Virus Infection.A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies.Viral evasion and challenges of hepatitis C virus vaccine development.Expression, immunogenicity and diagnostic value of envelope proteins from an Egyptian hepatitis C virus isolate.Generation and Characterization of Monoclonal Antibodies against a Cyclic Variant of Hepatitis C Virus E2 Epitope 412-422.Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection.Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus.The dynamic properties of the Hepatitis C Virus E2 envelope protein unraveled by molecular dynamics.Structure-Based Design of Hepatitis C Virus Vaccines that Elicit Neutralizing Antibody Responses to a Conserved Epitope.Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge.Prevention of allograft HCV recurrence with peri-transplant human monoclonal antibody MBL-HCV1 combined with a single oral direct-acting antiviral: A proof-of-concept study.Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies.Use of host-like peptide motifs in viral proteins is a prevalent strategy in host-virus interactions.Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1.Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.

P2860

Q26801759-2AFDBBDF-B830-43EB-AB73-C87853612E87 Q30364309-7669C5E1-6F9E-426D-9584-AF959D4B565E Q30374314-6E836ECF-6523-4F05-923E-914C359F964F Q33612608-FECE416C-DFB9-40C5-9AF1-4F8B479DDF36 Q33691856-D07B510B-9D09-4BC4-BA3B-98C95562B39A Q34047477-C7C130D6-3982-4E59-B8B5-818F1A32F70D Q34594027-287AFD78-EF76-4D1B-A092-23718AA7766F Q35193285-C3E53273-AB86-4808-AC09-8DC1190A57D7 Q35450992-00099676-0012-4408-BBE1-D0B09CFCF2EF Q35630492-B3AB9A05-6356-4C23-8863-B2BB57453E43 Q35913863-5B033AA8-153A-4D7B-BEF4-B9A68403F258 Q35942829-96CCCC26-93CD-446E-AE15-0C00CBB75C08 Q36096436-6D701AAC-5D5B-4A16-A3F9-A0565F20A1DA Q36215733-BAA8C194-3A82-4236-903B-37D895A45492 Q36288404-10277594-2011-430B-89C3-79D48C7F54AC Q36290295-02F052C1-534E-4FD2-B41D-38FCC5E6D8DC Q36444225-E5AEE79A-A482-41CE-BDF1-0F19510BB0D8 Q36576382-1C4A46F0-D579-4B6B-B297-397917F0BC70 Q37417839-187F1933-29B7-48CF-8BFE-DD6A4350A017 Q37417999-FFC07FA3-B96B-419F-9360-76CB66B06AB4 Q38128299-1061D10B-B553-45C4-BE85-BD9D355FBAC1 Q38192357-4D32DA5D-8501-4FEB-90DA-963DDE72A5EC Q38244787-9CF5C563-6506-4805-924E-D0E94536842F Q38765582-8DBADF9C-9DB9-460B-AFB1-A2CCF4CCA393 Q38809451-4A931C54-0087-424B-B466-25FB612704E8 Q38856649-19CD6751-C466-4F43-8138-2A08742F7E82 Q38961608-D861C62F-F887-4D65-853F-32A311F30711 Q39046601-8721DAD8-DD5B-421F-B1F7-9866FAF87005 Q39062848-6569D45E-A5C4-42C4-8CBB-7B472960AB47 Q39327457-F6058CDD-3C2C-4FB3-9335-70A8B5D05E4B Q39403799-4089B8C1-547C-4A13-998C-C3B141F1FEC6 Q39602767-2878243F-CDA1-4D5D-97D9-4CDD42F780A9 Q39923648-9B75E08B-0838-4B71-A946-8B76D51A54A5 Q40088796-4499761E-43A6-45A8-A8A2-D7C815C7625C Q40165519-EE97BCDC-FE6A-41FD-A256-88A194280516 Q40356307-24F7B41F-8B62-42FF-B11A-F5B65898D30D Q41619358-BFF2D5DC-30DC-485F-B119-D27800310AC0 Q42215545-1E166A62-7EED-4D2B-A278-48510C542C35 Q45324948-B768242A-AEE7-4411-85E4-193078DA6817 Q52375192-10338169-24F7-49A9-83BB-078355BBF483

P2860

Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies

http://www.wikidata.org/entity/Q27684112

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

Glycan shifting on hepatitis C ...... roadly neutralizing antibodies

@ast

Glycan shifting on hepatitis C ...... roadly neutralizing antibodies

@en

Glycan shifting on hepatitis C ...... roadly neutralizing antibodies

@nl

type

label

Glycan shifting on hepatitis C ...... roadly neutralizing antibodies

@ast

Glycan shifting on hepatitis C ...... roadly neutralizing antibodies

@en

Glycan shifting on hepatitis C ...... roadly neutralizing antibodies

@nl

prefLabel

Glycan shifting on hepatitis C ...... roadly neutralizing antibodies

@ast

Glycan shifting on hepatitis C ...... roadly neutralizing antibodies

@en

Glycan shifting on hepatitis C ...... roadly neutralizing antibodies

@nl

P1433

Q27684112-D202D12F-4C1C-441D-B0D8-0E653375399E

P1476

Q27684112-60842A5F-41C4-4717-8308-B85544691F1B

P2093

Q27684112-011548EB-9F07-42C3-AE97-1B5873645E85

Q27684112-0AE4A124-9CF2-4076-AB7D-E013B1D55D99

Q27684112-0B26A001-81A3-4985-9705-55476542B3F3

Q27684112-52524844-E3F1-4E3C-9A4F-70614AE5F0FF

Q27684112-5391633A-5DBB-4BF9-8D06-58AD79D08D40

Q27684112-54DBCB3B-AD0A-4998-BCF2-B619773108DE

Q27684112-5BE144A6-6E39-4872-A5A4-B1B26F4D523F

Q27684112-69599D89-31C7-4920-82E8-F32A70E52C78

Q27684112-6A020C96-6C80-4AAF-81AE-93EA18129741

Q27684112-71B00014-44AA-4E4B-84A2-3BD6766E2336

P304

Q27684112-98FF0A93-3433-4C62-ADE2-8616CFBBC44E

P31

Q27684112-19BC56ED-E839-4D48-86F7-21B9AF0CBD8C

P356

Q27684112-C439D88E-46E0-4271-AB23-4410056E8F4F

P407

Q27684112-490BB99B-A2E4-481E-84E1-1B6AD93A5051

P433

Q27684112-A79A63F2-9646-4BA9-8BF3-35EEC528B548

P478

Q27684112-0A21B962-E0F8-4078-900A-2CE54DD50C36

P50

Q27684112-03C04092-271D-46AC-ABF6-82DFEA9ABF5D

Q27684112-B7D28B4A-F322-4DD1-8DC8-AB6766E8DE50

P577

Q27684112-1CBFA6A6-3D88-4494-BF8D-C41150288E4A

P5875

Q27684112-9A49093F-8A79-4997-ADD7-56E84DEC1597

P698

Q27684112-3AD2794D-4444-4E36-8BDC-69658E7BEDC6

P921

Q27684112-31D6C1C1-4314-48CF-8EF8-5E72FAE5A5B8

P356

J.JMB.2013.02.025

P1433

Journal of Molecular Biology

P1476

Glycan shifting on hepatitis C ...... roadly neutralizing antibodies

@en

P2093

Alex Brown

http://www.w3.org/2001/XMLSchema#string

Arvind H Patel

http://www.w3.org/2001/XMLSchema#string

David Arnott

http://www.w3.org/2001/XMLSchema#string

David J Matthews

http://www.w3.org/2001/XMLSchema#string

Homer Pantua

http://www.w3.org/2001/XMLSchema#string

Jingyu Diao

http://www.w3.org/2001/XMLSchema#string

Jo-Anne Hongo

http://www.w3.org/2001/XMLSchema#string

Kentaro Takeda

http://www.w3.org/2001/XMLSchema#string

Krista McCutcheon

http://www.w3.org/2001/XMLSchema#string

Mary Mathieu

http://www.w3.org/2001/XMLSchema#string

P304

1899-914

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JMB.2013.02.025

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

425

http://www.w3.org/2001/XMLSchema#string

P50

Charles Eigenbrot

P577

2013-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235785752

http://www.w3.org/2001/XMLSchema#string

P698

23458406

http://www.w3.org/2001/XMLSchema#string

P921